News Headlines

31. Naobios, Nuvonis And European Vaccine Initiative Collaborate On Manufacturing Influenza Challenge Agent 9/2/2025

    Naobios, a CDMO providing bioprocess development and good manufacturing practices (GMP) production of clinical batches of virus-based products, Nuvonis, a biotechnological company providing innovative cell banks for the production of vaccines and other biologicals, and the European Vaccine Initiative (EVI), a leading European non-profit Product Development Partnership (PDP), today announce a joint effort through the Inno4Vac consortium to develop an influenza A(H3N2) Human Viral Challenge Agent with the long-term goal of addressing the low effectiveness of seasonal influenza vaccines in fighting influenza A(H3N2).

32. Thermo Fisher Scientific Completes Acquisition Of Sanofi's Ridgefield, New Jersey Site 9/2/2025

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced the completion of its acquisition of Sanofi’s state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companies’ strategic partnership to enable additional U.S. drug product manufacturing.

33. LOTTE BIOLOGICS Establishes Contract Manufacturing Partnership With A Leading U.S. Biopharmaceutical Company 9/1/2025

    LOTTE BIOLOGICS (CEO James Park) today announced that it has entered a late-stage to commercial contract manufacturing partnership with a U.S.-based global biopharmaceutical company.

34. Accro Bioscience And Fosun Pharma Announce Exclusive License Agreement For AC-201, A Highly Selective TYK2/JAK1 Inhibitor In Greater China 8/29/2025

    Accro Bioscience and Fosun Pharma today announced that Accro will grant exclusive rights to develop, manufacture, and commercialize its independently developed, highly selective TYK2/JAK1 inhibitor to Fosun Pharma in Greater China (including Chinese Mainland, Hong Kong SAR, and Macau SAR).

35. Indena And TCG GreenChem Join Forces To Advance Next-Generation ADC Technologies 8/28/2025

    Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers, the key component of Antibody-Drug Conjugates (ADCs).

36. Sai Life Sciences Completes Phase II Of Production Block 11 At Bidar Site, India, Expands Capacity To 700 KL 8/28/2025

    Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV).

37. Piramal Pharma Solutions Supports George Medicines In Developing Its New Drug For Hypertension, WIDAPLIK™ (telmisartan, amlodipine And indapamide) 8/28/2025

    George Medicines, a leading late-stage biopharma company, in partnership with Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635)developed WIDAPLIK, a new drug for treatment of hypertension in adult patients, including as initial treatment, to lower blood pressure.

38. IQVIA And Flagship Pioneering Announce Strategic Collaboration To Accelerate The Development Of Breakthrough Life Sciences Companies 8/28/2025

    IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the bioplatform innovation company, today announced a strategic collaboration to accelerate the development of breakthrough life sciences companies.

39. Asimov Announces Cell Line Development Partnership With Ottimo Pharma To Accelerate Cancer Immunotherapy's Path To Clinic 8/27/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a cell line development partnership with Ottimo Pharma, a biopharmaceutical company developing first-in-class, one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of people living with cancer.

40. Hengdian Group's Apeloa Pharmaceutical Uses Flow Chemistry For Sustainable Manufacturing 8/27/2025

    Hengdian Group’s pharmaceutical arm Apeloa is using Flow Chemistry, a safer and more environmentally-friendly manufacturing approach than traditional batch processing, to drive sustainability in the pharmaceutical industry.